Developing new antibiotics to fight resistant bacterial infections
Evaluation of Streptamine Analogs to Overcome Resistance to Apramycin
This study is working on improving a new antibiotic called apramycin to help fight tough bacterial infections that don't respond to regular treatments, especially for people dealing with multidrug-resistant infections.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Georgia NIH-funded |
| Lab location | 1 site (Athens, United States) |
| Project ID | NIH-10738751 on NIH RePORTER |
What this research studies
This research focuses on creating advanced versions of apramycin, a novel antibiotic, to combat bacterial infections that have become resistant to current treatments. The approach involves modifying the chemical structure of apramycin to enhance its effectiveness against specific resistance mechanisms. By testing these new analogs, the research aims to provide solutions for treating multidrug-resistant Gram-negative infections, which are a significant challenge in healthcare today.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from multidrug-resistant bacterial infections, particularly those caused by Gram-negative bacteria.
Not a fit: Patients with infections caused by bacteria that are not resistant to current antibiotics may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new antibiotics that effectively treat infections resistant to existing medications.
How similar studies have performed: Previous research has shown promise in developing new antibiotics to overcome resistance, indicating that this approach could yield significant advancements.
Where this research is happening
Athens, United States
- University of Georgia — Athens, United States (Active)
Researchers
- Principal investigator: Crich, David — University of Georgia
- Study coordinator: Crich, David
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.